GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Ccl5 | increases expression | EXP | | 6480464 | CTD | Lipopolysaccharides results in increased expression of CCL5 mRNA; Lipopolysaccharides results in increased expression of CCL5 protein | PMID:28693884 PMID:33727093 | Ccl5 | multiple interactions | EXP | | 6480464 | CTD | Lipopolysaccharides inhibits the reaction [Rutin results in decreased expression of CCL5 mRNA] | PMID:28693884 | Ccl5 | increases expression | ISO | CCL5 (Homo sapiens) | 6480464 | CTD | Lipopolysaccharides results in increased expression of CCL5 mRNA; Lipopolysaccharides results in increased expression of CCL5 protein | PMID:15460210 PMID:18684396 PMID:19428942 PMID:21147091 PMID:24707119 PMID:27568862 PMID:35811015 | Ccl5 | increases expression | ISO | Ccl5 (Mus musculus) | 6480464 | CTD | Lipopolysaccharides results in increased expression of CCL5 mRNA; Lipopolysaccharides results in increased expression of CCL5 protein | PMID:19133137 PMID:19627980 PMID:21979172 PMID:22169119 PMID:22225513 PMID:23958496 PMID:25780039 PMID:25890327 PMID:26582142 PMID:27170112 PMID:27339419 | Ccl5 | increases secretion | ISO | CCL5 (Homo sapiens) | 6480464 | CTD | Lipopolysaccharides results in increased secretion of CCL5 protein | PMID:15289356 PMID:16367934 PMID:18390722 PMID:28065790 | Ccl5 | increases secretion | ISO | Ccl5 (Mus musculus) | 6480464 | CTD | Lipopolysaccharides results in increased secretion of CCL5 protein | PMID:24561310 PMID:32800949 | Ccl5 | multiple interactions | ISO | CCL5 (Homo sapiens) | 6480464 | CTD | 1,25-dihydroxyvitamin D inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL5 protein]; [Homocysteine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein; [Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of CCL5 mRNA; [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of CCL5 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA; coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; Dimethyl Sulfoxide inhibits the reaction [[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased secretion of CCL5 protein]; fexofenadine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; fexofenadine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; hesperetin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; Lipopolysaccharides promotes the reaction [Shiga Toxin 2 results in increased secretion of CCL5 protein]; Phloretin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; Silymarin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein] | PMID:15460210 PMID:16225753 PMID:16366002 PMID:16367934 PMID:21878375 PMID:24707119 PMID:27568862 PMID:35811015 | Ccl5 | multiple interactions | ISO | Ccl5 (Mus musculus) | 6480464 | CTD | (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; 4-hydroxy-2-nonenal inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; 4-hydroxy-2-nonenal inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL5 mRNA; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL5 protein; [procyanidin B3 co-treated with Eicosapentaenoic Acid] inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; [Shiga Toxin 2 co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; APPL1 protein promotes the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL5 protein]; Cathelicidins inhibits the reaction [[Shiga Toxin 2 co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; IL6 protein affects the reaction [Lipopolysaccharides results in increased secretion of CCL5 protein]; Lipopolysaccharides inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; Lipopolysaccharides promotes the reaction [RELA protein binds to CCL5 promoter]; Lipopolysaccharides results in increased expression of and results in increased secretion of CCL5 protein; luteolin 3'-glucuronide inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; luteolin-7-O-glucuronide inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; mangiferin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL5 protein]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL5 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; terameprocol inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to CCL5 promoter]]; trametinib promotes the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein]; Wortmannin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA] | PMID:15135318 PMID:15804595 PMID:19627980 PMID:21138578 PMID:21146893 PMID:21731756 PMID:22169119 PMID:22225513 PMID:23958496 PMID:24561310 PMID:25780039 PMID:26582142 PMID:26918785 PMID:27170112 PMID:29730267 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |